The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Personalized neoantigen dendritic cell vaccine LK101 as maintenance in NSCLC
Han Chong Toh, MD, National Cancer Centre Singapore, Singapore, discusses early results from a Phase Ib/IIa study (NCT05886439) of LK101, a personalized mRNA-transfected dendritic cell vaccine targeting multiple neoantigens, given with tislelizumab as first-line maintenance therapy in locally advanced or metastatic non-small cell lung cancer (NSCLC). The approach showed manageable safety, robust neoantigen-specific T cell responses and preliminary antitumor activity. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So that was part of the rapid oral investigational immunotherapy session, and it was an interesting study. It was a study that came out of a Chinese company, run by a PI from Beijing. Essentially, it was to look at a new antigen cancer vaccine on the backbone of a dendritic cell as the vaccine platform, and it was kind of to see whether you can improve the outcomes of metastatic lung cancer, non-small cell lung cancer in the first-line setting...
So that was part of the rapid oral investigational immunotherapy session, and it was an interesting study. It was a study that came out of a Chinese company, run by a PI from Beijing. Essentially, it was to look at a new antigen cancer vaccine on the backbone of a dendritic cell as the vaccine platform, and it was kind of to see whether you can improve the outcomes of metastatic lung cancer, non-small cell lung cancer in the first-line setting. So essentially when you give the chemo and after you give the chemo you give the immune checkpoint inhibitor, the idea is whether the addition of a cancer vaccine can bring even more benefit in terms of progression-free survival, safety and toxicities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
